Major histocompatibility complex class II molecules presenting New York esophageal squamous cell carcinoma 1 peptides (MHC II-NY-ESO-1)

Major histocompatibility complex (MHC) class II molecules presenting New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptides are critical targets for cancer immunotherapy. NY-ESO-1, encoded by the CTAG1B gene, is a prominent cancer-testis antigen expressed in numerous malignancies but absent in normal adult somatic tissues, providing a high degree of tumor specificity (PMID: 9060360, UniProt P78358). While much research has focused on MHC class I presentation to CD8+ T cells, the presentation of NY-ESO-1 peptides by MHC class II molecules (such as HLA-DP4 or HLA-DR) to CD4+ T cells is essential for a sustained and effective anti-tumor immune response (PMID: 10944165). These complexes facilitate the activation of helper T cells, which secrete cytokines like interferon-gamma and provide necessary signals for the maturation of cytotoxic T cells and B cells. Therapeutic interventions targeting these complexes include TCR-engineered T cells (TCR-T) and peptide-based vaccines, which aim to enhance the visibility of tumor cells to the immune system and overcome tumor-induced immunosuppression (PMID: 25132036). Clinical development often involves identifying patients who are both positive for NY-ESO-1 expression and possess specific HLA alleles, such as HLA-DPB1*04:01, to ensure proper antigen presentation. Monitoring these complexes is vital for evaluating the efficacy of immunotherapies and understanding mechanisms of resistance, such as the loss of HLA expression by tumor cells.

Other names

HLA class II-NY-ESO-1 complexCTAG1B-MHC II complexNY-ESO-1-HLA-DP/DQ/DR complexCancer-testis antigen 1B-MHC II complexNY-ESO-1 peptide-HLA class II complex

Recognition of the NY-ESO-1 peptide-MHC class II complex by specific T-cell receptors (TCRs) on CD4+ T cells, which triggers T-cell activation, the release of pro-inflammatory cytokines (e.g., IFN-gamma), and the recruitment of other immune effectors to the tumor microenvironment (PMID: 10944165, PMID: 15634878).